As reported by the New York Times on Sept. 13, 2019:
The Food and Drug Administration said on Friday that it had detected low levels of a cancer-causing contaminant in samples of heartburn medicines containing the drug commonly known as Zantac.
It was advising patients who take over-the-counter versions to consider switching to a different medication.
But no recalls have been initiated, and the agency said patients who take prescription versions of the drug, known as ranitidine, should consult with their doctors before stopping. The European Medicines Agency is also looking into the issue.
Zantac, the brand-name version of the drug, is sold by Sanofi, but generic versions are widely sold. The F.D.A. has not identified any specific products that were affected.
A spokeswoman for Sanofi said the company does not plan to recall the product.
“Sanofi takes patient safety seriously, and we are committed to working with the F.D.A.,” the spokeswoman, Ashleigh Koss, said in a statement. The over-the-counter version of Zantac “has been around for over a decade and meets all the specified safety requirements for use in the O.T.C. market.”
Sauder Schelkopf is a nationally recognized class action and personal injury law firm. The firm’s partners currently serve as court appointed lead counsel in courts across the country and have been selected by the National Trial Lawyers Association as some of the Top 100 Trial Lawyers in Pennsylvania since 2012. The attorneys at Sauder Schelkopf have recovered over $500 million on behalf of their clients and class members.
We Want to Hear from You
You can contact the attorneys at Sauder Schelkopf by submitting your information or calling 888.711.9975.